Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy

被引：16
作者：
Abcouwer, Steven F. [1 ]
机构：
[1] Univ Michigan, Coll Med, Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA
来源：
DIABETES | 2013年 / 62卷 / 01期
关键词：
PROTEIN-KINASE ACTIVATION; NF-KAPPA-B; ENDOTHELIAL-CELLS; EXPRESSION; TRIAL; TARGET; GROWTH;
D O I：
10.2337/db12-1223
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：36 / 38
页数：3
相关论文
共 21 条
  • [1] Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
    Chen, Ying
    Hu, Yang
    Lin, Mingkai
    Jenkins, Alicia J.
    Keech, Anthony C.
    Mott, Robert
    Lyons, Timothy J.
    Ma, Jian-xing
    [J]. DIABETES, 2013, 62 (01) : 261 - 272
  • [2] Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes.
    Chew, Emily Y.
    Ambrosius, Walter T.
    Davis, Matthew D.
    Danis, Ronald P.
    Gangaputra, Sapna
    Greven, Craig M.
    Hubbard, Larry
    Esser, Barbara A.
    Lovato, James F.
    Perdue, Letitia H.
    Goff, David C., Jr.
    Cushman, William C.
    Ginsberg, Henry N.
    Elam, Marshall B.
    Genuth, Saul
    Gerstein, Hertzel C.
    Schubart, Ulrich
    Fine, Lawrence J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03) : 233 - 244
  • [3] PPAR activators inhibit endothelial cell migration by targeting Akt
    Goetze, S
    Eilers, F
    Bungenstock, A
    Kintscher, U
    Stawowy, P
    Blaschke, F
    Graf, K
    Law, RE
    Fleck, E
    Gräfe, M
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (05) : 1431 - 1437
  • [4] Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
    Hemmingsen, Bianca
    Lund, Soren S.
    Gluud, Christian
    Vaag, Allan
    Almdal, Thomas
    Hemmingsen, Christina
    Wetterslev, Jorn
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2011, 343 : 1136
  • [5] PPARα: an emerging therapeutic target in diabetic microvascular damage
    Hiukka, Anne
    Maranghi, Marianna
    Matikainen, Niina
    Taskinen, Marja-Riitta
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2010, 6 (08) : 454 - 463
  • [6] Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study
    Huang, W. P.
    Yin, W. H.
    Chen, J. W.
    Jen, H. L.
    Young, M. S.
    Lin, S. J.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2009, 39 (09) : 775 - 783
  • [7] Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial
    Keech, A. C.
    Mitchell, P.
    Summonen, P. A.
    O'Day, J.
    Davis, T. M. E.
    Moffitt, M. S.
    Taskinen, M. R.
    Simes, R. J.
    Tse, D.
    Williamson, E.
    Merrifield, A.
    Laatikainen, L. T.
    d'Emden, M. C.
    Crimet, D. C.
    O'Connell, R. L.
    Colman, P. G.
    [J]. LANCET, 2007, 370 (9600) : 1687 - 1697
  • [8] Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway
    Kim, Jaetaek
    Ahn, Ji-Hyun
    Kim, Jeong-Hun
    Yu, Young-Suk
    Kim, Ho-Shik
    Ha, Joohun
    Shinn, Soon-Hyun
    Oh, Yeon-Sahng
    [J]. EXPERIMENTAL EYE RESEARCH, 2007, 84 (05) : 886 - 893
  • [9] Kraja Aldi T., 2010, Endocrine Metabolic & Immune Disorders-Drug Targets, V10, P138
  • [10] Effect of glycemic exposure on the risk of microvascular complications in the diabetes trial - Revisited
    Lachin, John M.
    Genuth, Saul
    Nathan, David M.
    Zinman, Bernard
    Rutledge, Brandy N.
    [J]. DIABETES, 2008, 57 (04) : 995 - 1001
123